Inflammation and clinical response to treatment in depression: A meta-analysis

Strawbridge, R.; Arnone, D.; Danese, A.; Papadopoulos, A.; Herane Vives, A.; Cleare, A.J.

doi:10.1016/j.euroneuro.2015.06.007

Cited by 666Tryptophan and brain disordersTreatment of Major DepressionStress Responses and Cortisol

Inflammation and clinical response to treatment in depression: A meta-analysis

Open access

Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J.·2015·European Neuropsychopharmacology

DOI 10.1016/j.euroneuro.2015.06.007

Open this paper in CoChat — free account

Abstract

The depressive state has been characterised as one of elevated inflammation, which holds promise for better understanding treatment-resistance in affective disorders as well as for future developments in treatment stratification. Aiming to investigate alterations in the inflammatory profiles of individuals with depression as putative biomarkers for clinical response, we conducted meta-analyses examining data from 35 studies that investigated inflammation before and after treatment in depressed patients together with a measure of clinical response. There were sufficient data to analyse IL-6, TNFα and CRP. Levels of IL-6 decreased with antidepressant treatment regardless of outcome, whereas persistently elevated TNFα was associated with prospectively determined treatment resistance. Treatment non-responders tended to have higher baseline inflammation, using a composite measure of inflammatory markers. Our findings suggest that elevated levels of inflammation are contributory to treatment resistance. Combining inflammatory biomarkers might prove a useful tool to improve diagnosis and detection of treatment refractoriness, and targeting persistent inflammation in treatment-resistant depression may offer a potential target for the development of novel intervention strategies.

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2015.06.007

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Two recent meta-analyses found different results regarding changes in peripheral levels of immune mediators after antidepressant treatment.
“Furthermore, two recent metaanalysis found different results regarding changes in peripheral levels immune mediators after antidepressant treatment [31,32].”
From Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis (2017) · cites this paper as [31]
The largest previous meta-analysis synthesized data from 35 original studies.
“The largest previous metaanalysis synthesized data from 35 original studies [31].”
From Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis (2017) · cites this paper as [31]
The previous meta-analysis included several treatments other than antidepressant drugs.
“However, this meta-analysis included several treatments other than antidepressant drugs, as well as participants with bipolar depression, and also included studies in which part of the sample had significant baseline comorbidities [31].”
From Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis (2017) · cites this paper as [31]
The previous meta-analysis included participants with bipolar depression.
“However, this meta-analysis included several treatments other than antidepressant drugs, as well as participants with bipolar depression, and also included studies in which part of the sample had significant baseline comorbidities [31].”
From Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis (2017) · cites this paper as [31]
The previous meta-analysis included studies in which part of the sample had significant baseline comorbidities.
“However, this meta-analysis included several treatments other than antidepressant drugs, as well as participants with bipolar depression, and also included studies in which part of the sample had significant baseline comorbidities [31].”
From Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis (2017) · cites this paper as [31]

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · see citing works
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · see citing works
Untitled work
(2008) · Cited by 3,790 · see citing works
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · see citing works
A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression: The Role of Baseline Inflammatory Biomarkers
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · see citing works
The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · see citing works
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931 · see citing works
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914 · see citing works
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894 · see citing works
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794 · see citing works
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770 · see citing works
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · see citing works
INCREASED SERUM IL-6 AND IL-1 RECEPTOR ANTAGONIST CONCENTRATIONS IN MAJOR DEPRESSION AND TREATMENT RESISTANT DEPRESSION
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728 · see citing works
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727 · see citing works
The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700 · see citing works
Increased Plasma Concentrations of Interleukin-6, Soluble Interleukin-6, Soluble Interleukin-2 and Transferrin Receptor in Major Depression
Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00028-l · Cited by 622 · see citing works
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 477 · see citing works
Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis
Arnone, D., Cavanagh, J., Gerber, D., Lawrie, S. M., Ebmeier, K. P., & McIntosh, A. M. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.059717 · Cited by 441 · see citing works
Self-citation
An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline
Uher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010094 · Cited by 418 · see citing works
Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis
Munkholm, K., Braüner, J. V., Kessing, L. V., & Vinberg, M. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.05.018 · Cited by 402 · see citing works
Clinical trial of adjunctive Celecoxib treatment in patients with major depression: a double blind and placebo controlled trial
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397 · see citing works
Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder
Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391 · see citing works
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission
Frommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362 · see citing works
Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells
Xia, Z., DePierre, J. W., & Nässberger, L. (1996) · Immunopharmacology · doi:10.1016/0162-3109(96)00111-7 · Cited by 318 · see citing works
Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis
Mikovа, O. E., Yakimova, R., Bosmans, E., Kenis, G., & Maes, M. H. J. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00081-5 · Cited by 299 · see citing works
What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies
Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A. S., & Cleare, A. J. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.014 · Cited by 299 · see citing works
Self-citation
Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298 · see citing works
Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder
Eller, T., Vasar, V., Shlik, J., & Maron, E. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.015 · Cited by 290 · see citing works
Microglia in the developing brain: a potential target with lifetime effects
Harry, G. J., & Kraft, A. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.01.012 · Cited by 250 · see citing works
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240 · see citing works
Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression
Yoshimura, R., Hori, H., Ikenouchi, A., Umene‐Nakano, W., Ueda, N., & Nakamura, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.03.020 · Cited by 227 · see citing works
IL-6 levels decrease with SSRI treatment in patients with major depression
Başterzi, A. D., Aydemir, Ç., Kısa, C., Aksaray, S., Tüzer, V., Yazıcı, K., & Göka, E. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.717 · Cited by 219 · see citing works
Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis
Hiles, S. A., Baker, A., de Malmanche, T., & Attia, J. (2012) · Psychological Medicine · doi:10.1017/s0033291712000128 · Cited by 218 · see citing works
Clinical features of treatment-resistant depression.
Kornstein, S. G., & Schneider, R. K. (2001) · PubMed · Cited by 216 · see citing works
Effects of Cytokines on Glucocorticoid Receptor Expression And Function: Glucocorticoid Resistance and Relevance to Depression
Miller, A. H., Pariante, C. M., & Pearce, B. D. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_7 · Cited by 203 · see citing works
Imbalance between Pro- and Anti-inflammatory Cytokines, and between Th1 and Th2 Cytokines in Depressed Patients: The Effect of Electroacupuncture or Fluoxetine Treatment
Song, C., Halbreich, U. M., Han, C., Leonard, B. E., & Luo, H. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1202263 · Cited by 187 · see citing works
Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system
Carvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167 · see citing works
Self-citation
Untitled work
(2010) · PubMed · Cited by 157 · see citing works
Antidepressant therapy and C-reactive protein levels
O’Brien, S. M., Scott, L. V., & Dinan, T. G. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.011015 · Cited by 149 · see citing works
Inhibition of interferon γ induced interleukin 12 production: A potential mechanism for the anti-inflammatory activities of tumor necrosis factor
Hodge-Dufour, J., Marino, M. W., Horton, M. R., Jungbluth, A., Burdick, M. D., Strieter, R. M., Noble, P. W., Hunter, C. A., & Puré, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13806 · Cited by 144 · see citing works
Variations in Circulating Cytokine Levels during 52 Week Course of Treatment with SSRI for Major Depressive Disorder
Hernández, M. E., Mendieta, D., Martínez-Fong, D., Loría, F., Moreno, J., Estrada, I., Bojalil, R., & Pavón, L. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.001 · Cited by 140 · see citing works
Pro-inflammatory biomakers in depression: Treatment with venlafaxine
Piletz, J. E., Halaris, A. E., Iqbal, O., Hoppensteadt, D., Fareed, J., Zhu, H., Sinacore, J. M., & DeVane, C. L. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802573246 · Cited by 130 · see citing works
Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C
Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.05.001 · Cited by 130 · see citing works
The ratio of cortisol/DHEA in treatment resistant depression
Markopoulou, K., Papadopoulos, A. S., Juruena, M. F., Poon, L., Pariante, C. M., & Cleare, A. J. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.004 · Cited by 129 · see citing works
Self-citation
Major depressive disorder is associated with elevated monocyte counts
Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., & Kirchner, H. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb09849.x · Cited by 123 · see citing works
A Psychological Intervention Reduces Inflammatory Markers by Alleviating Depressive Symptoms: Secondary Analysis of a Randomized Controlled Trial
Thornton, L. M., Andersen, B. L., Schuler, T. A., & Carson, W. E. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181b0545c · Cited by 122 · see citing works
Successful Antidepressant Therapy Restores the Disturbed Interplay Between TNF-α System and HPA Axis
Himmerich, H., Binder, E. B., Kunzel, H. E., Schuld, A., Lucae, S., Uhr, M., Pollmächer, T., Holsboer, F., & Ising, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.075 · Cited by 120 · see citing works
Treatment response and cognitive impairment in major depression: Association with C-reactive protein
Chang, H. H., Lee, I. H., Gean, P. W., Lee, S.-Y., Chi, M. H., Yang, Y. K., Lu, R.-B., & Chen, P. S. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.07.239 · Cited by 120 · see citing works
Regulatory T cells increased while IL-1β decreased during antidepressant therapy
Himmerich, H., Milenović, S., Fulda, S., Plümäkers, B., Sheldrick, A. J., Michel, T. M., Kircher, T., & Rink, L. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.005 · Cited by 116 · see citing works
Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance
Juruena, M. F., Pariante, C. M., Papadopoulos, A. S., Poon, L., Lightman, S. L., & Cleare, A. J. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050278 · Cited by 112 · see citing works
Self-citation
Cytokine profiles in women with different subtypes of major depressive disorder
Marques-Deak, A., NETO, F., Dominguez, W. V., Solis, A. C. D. O., Kurcgant, D., Sato, F. P., Ross, J. M., & Prado, E. D. F. G. B. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.11.003 · Cited by 111 · see citing works
Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.
Kubera, M., Kenis, G., Bosmans, E., Zieba, A., Dudek, D., Nowak, G., & Maes, M. H. J. (2000) · PubMed · Cited by 110 · see citing works
Olfactory Bulbectomy Provokes a Suppression of Interleukin-1β and Tumour Necrosis Factor-α Production in Response to an in vivo Challenge with Lipopolysaccharide: Effect of Chronic Desipramine Treatment
Connor, T. J., Harkin, A., Kelly, J. P., & Leonard, B. E. (1999) · NeuroImmunoModulation · doi:10.1159/000026417 · Cited by 80 · see citing works
Depression and immunity: clinical factors and therapeutic course
Schleifer, S. J., Keller, S. E., & Bartlett, J. A. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(98)00133-4 · Cited by 69 · see citing works
Plasma levels of interleukin‐6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder
Yoshimura, R., Hori, H., Ikenouchi, A., Umene‐Nakano, W., Katsuki, A., Atake, K., & Nakamura, J. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2333 · Cited by 62 · see citing works
Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds
Fornaro, M., Rocchi, G., Escelsior, A., Contini, P., & Martino, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.08.007 · Cited by 59 · see citing works
Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy
Landmann, R. M., Schaub, B., Link, S., & Wacker, H. R. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00176-x · Cited by 55 · see citing works
Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: Relationships with immune-inflammatory markers
Maes, M. H. J., Meester, I. D., Verkerk, R. M., Medts, P. D., Wauters, A., Vanhoof, G., Vandoolaeghe, E., Neels, H. M., & Scharpé, S. (1997) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(96)00040-6 · Cited by 54 · see citing works
Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy
Harley, J., Luty, S., Carter, J., Mulder, R., & Joyce, P. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109102770 · Cited by 53 · see citing works
Cytokines, Stress, and Depression
Dantzer, R., Yirmiya, R., & Wollman, E. E. (1999) · Advances in experimental medicine and biology · doi:10.1007/b102345 · Cited by 51 · see citing works
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Fornaro, M., Martino, M., Battaglia, F., Colicchio, & Perugi, G. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s16382 · Cited by 45 · see citing works
Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission
Tsai, S., Chung, K., Huang, S., Chen, P., Lee, H., & Kuo, C. (2014) · Bipolar Disorders · doi:10.1111/bdi.12240 · Cited by 43 · see citing works
Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder
Eller, T., Vasar, V., Shlik, J., & Maron, E. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091077 · Cited by 40 · see citing works
Depression and immunity: The biochemical interrelationship between the central nervous system and the immune system
Kook, A. I., Mizruchin, A., Odnopozov, N., Gershon, H. E., & Segev, Y. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00038-i · Cited by 33 · see citing works
Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: A flow cytometric analysis
Başterzi, A. D., Yazıcı, K. U., Buturak, V., Çimen, B., Yazıcı, A., Eskandari, G., Acar, Ş. T., & Taşdelen, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.09.025 · Cited by 31 · see citing works
Comparison of the effects of dopaminergic and serotonergic activity in the CNS on the activity of the immune system
Mizruchin, A., Gold, I., Krasnov, I. B., Livshitz, G., Shahin, R., & Kook, A. I. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00144-7 · Cited by 28 · see citing works
Clinical response augments NK cell activity independent of treatment modality: a randomized double-blind placebo controlled antidepressant trial
Frank, M. G., Hendricks, S. E., Burke, W. J., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001272 · Cited by 25 · see citing works
Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylimipramine treatment
Pariante, C. M., & Miller, A. H. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00040-v · Cited by 11 · see citing works

Flagged first, then by citations

Sorted by citations

Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073 · see citing works
Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation
Brites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599 · see citing works
Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538 · see citing works
Oxidative stress, inflammation and treatment response in major depression
Lindqvist, D., Dhabhar, F. S., James, S. J., Hough, C. M., Jain, F. A., Bersani, F. S., Reus, V. I., Verhoeven, J. E., Epel, E. S., Mahan, L., et al. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.031 · Cited by 473 · see citing works
Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis
Köhler, C. A., Freitas, T. H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N. Q., Morris, G., Fernandes, B. S., Brunoni, A. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0632-1 · Cited by 449 · see citing works
What does plasma CRP tell us about peripheral and central inflammation in depression?
Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448 · see citing works
<p>Management of Treatment-Resistant Depression: Challenges and Strategies</p>
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446 · see citing works
Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432 · see citing works
Peripheral Cytokine Levels and Response to Antidepressant Treatment in Depression: A Systematic Review and Meta-Analysis
Liu, J. J., Wei, Y. B., Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B. S., Trivedi, M. H., Kelsoe, J. R., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0474-5 · Cited by 429 · see citing works
Self-citation
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415 · see citing works
Self-citation
Treatment-resistant depression and peripheral C-reactive protein.
Chamberlain, S. R., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D. N. C., Drevets, W. C., Cowen, P. J., Harrison, N. A., Pointon, L., Pariante, C. M., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.66 · Cited by 400 · see citing works
Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma?
Danese, A., & J Lewis, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.198 · Cited by 393 · see citing works
Self-citation
The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression
Mac Giollabhui, N., Ng, T. H., Ellman, L. M., & Alloy, L. B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00867-4 · Cited by 361 · see citing works
Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis
Leighton, S. P., Nerurkar, L., Krishnadas, R., Johnman, C., Graham, G. J., & Cavanagh, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.205 · Cited by 291 · see citing works
Hidden wounds? inflammatory links between childhood trauma and psychopathology
Danese, A., & Baldwin, J. R. (2017) · Annual Review of Psychology · doi:10.1146/annurev-psych-010416-044208 · Cited by 286 · see citing works
Self-citation
Yoga, Meditation and Mind-Body Health: Increased BDNF, Cortisol Awakening Response, and Altered Inflammatory Marker Expression after a 3-Month Yoga and Meditation Retreat
Cahn, B. R., Goodman, M. S., Peterson, C. T., Maturi, R., & Mills, P. J. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00315 · Cited by 292 · see citing works
“…states are associated with a propensity towards mental disorders such as depression and anxiety (Miller et al., 2009; Slavich and Irwin, 2014; Furtado and Katzman, 2015; Strawbridge et al., 2015) as well as an array of chronic medical illnesses (Aggarwal et al., 2006; Swardfager et al., 2010).”
Background
Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder
Haroon, E., Daguanno, A. W., Woolwine, B. J., Goldsmith, D. R., Baer, W. M., Wommack, E. C., Felger, J. C., & Miller, A. H. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.026 · Cited by 291 · see citing works
Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression
Köhler-Forsberg, O., Buttenschøn, H. N., Tansey, K. E., Maier, W., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.020 · Cited by 283 · see citing works
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267 · see citing works
Microbiome, inflammation, epigenetic alterations, and mental diseases
Alam, R., Abdolmaleky, H. M., & Zhou, J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32567 · Cited by 240 · see citing works
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233 · see citing works
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
The association between anxiety, traumatic stress, and obsessive–compulsive disorders and chronic inflammation: a systematic review and meta-analysis
Renna, M. E., O'Toole, M. S., Spaeth, P. E., Lekander, M., & Mennin, D. S. (2018) · Depression and Anxiety · doi:10.1002/da.22790 · Cited by 220 · see citing works
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214 · see citing works
Self-citation
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial
Jha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T., Grannemann, B., Soyombo, A., Mayes, T. L., Rush, A. J., & Trivedi, M. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.01.023 · Cited by 206 · see citing works
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197 · see citing works
The Long-Term Effect of Bariatric Surgery on Depression and Anxiety
Gill, H., Kang, S., Lee, Y., Rosenblat, J. D., Brietzke, E., Zuckerman, H., & McIntyre, R. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.113 · Cited by 191 · see citing works
Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health
Raony, Í., de Figueiredo, C. S., Pandolfo, P., Giestal-de-Araujo, E., Oliveira-Silva Bomfim, P., & Savino, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01170 · Cited by 185 · see citing works
Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut–microbiota–brain axis
Zhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.112 · Cited by 182 · see citing works
Neurobiological links between depression and AD: the role of TGF-β1 signaling as a new pharmacological target
Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172 · see citing works
The microbiota, immunoregulation, and mental health: implications for public health
Lowry, C. A., Smith, D. G., Siebler, P. H., Schmidt, D., Stamper, C. E., Hassell, J. E., Yamashita, P. S., Fox, J. H., Reber, S. O., Brenner, L. A., et al. (2016) · Current Environmental Health Reports · doi:10.1007/s40572-016-0100-5 · Cited by 172 · see citing works
The link between inflammation, bugs, the intestine and the brain in alcohol dependence
Leclercq, S., de Timary, P., Delzenne, N. M., & Stärkel, P. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.15 · Cited by 174 · see citing works
Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice
Yao, W., Zhang, J.-C., Ishima, T., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Suganuma, H., et al. (2016) · Scientific Reports · doi:10.1038/srep30659 · Cited by 154 · see citing works
Depression as a risk factor for Alzheimer’s disease: Genes, steroids, cytokines and neurogenesis – What do we need to know?
Herbert, J., & Lucassen, P. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.12.001 · Cited by 150 · see citing works
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152 · see citing works
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139 · see citing works
Self-citation
Depression and inflammation: correlation between changes in inflammatory markers with antidepressant response and long-term prognosis
Kofod, J., Elfving, B., Nielsen, E. H., Mors, O., & Köhler-Forsberg, O. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.09.006 · Cited by 136 · see citing works
Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far
Roman, M., & Irwin, M. R. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.09.016 · Cited by 132 · see citing works
On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: A systematic review
Pinto, J. V., Moulin, T. C., & Amaral, O. B. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.10.001 · Cited by 103 · see citing works
The potential of predictive analytics to provide clinical decision support in depression treatment planning
Kessler, R. C. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000377 · Cited by 103 · see citing works
Accelerating research on biological aging and mental health: Current challenges and future directions.
Han, L. K. M., Verhoeven, J. E., Tyrka, A. R., Penninx, B. W. J. H., Wolkowitz, O. M., Månsson, K. N. T., Lindqvist, D., Boks, M. P., Révész, D., Mellon, S. H., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.04.004 · Cited by 104 · see citing works
Depression and pain: primary data and meta-analysis among 237,952 people across 47 low- and middle-income countries
Stubbs, B., Vancampfort, D., Veronese, N., Thompson, T., Fornaro, M., Schofield, P., Solmi, M., Mugisha, J., Carvalho, A. F., & Koyanagi, A. (2017) · Psychological Medicine · doi:10.1017/s0033291717001477 · Cited by 102 · see citing works
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102 · see citing works
Anti-Depressive-like Behaviors of APN KO Mice Involve Trkb/BDNF Signaling Related Neuroinflammatory Changes
Li, W., Ali, T., Zheng, C., He, K., Liu, Z., Shah, F. A., Li, N., Yu, Z.-J., & Li, S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01327-3 · Cited by 80 · see citing works
The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review
Webb, L. M., Phillips, K. E., Ho, M. C., Veldic, M., & Blacker, C. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030826 · Cited by 84 · see citing works
Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: novel T cell biomarker for antidepressant medication selection
Jha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T. L., Mayes, T. L., & Trivedi, M. H. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.005 · Cited by 79 · see citing works
Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants
Martín-Hernández, D., Caso, J. R., Javier Meana, J., Callado, L. F., Madrigal, J. L. M., García-Bueno, B., & Leza, J. C. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1294-2 · Cited by 80 · see citing works
Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review
Woo, Y., Seo, H.-J., McIntyre, R., & Bahk, W.-M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010080 · Cited by 79 · see citing works
Neuroinflammatory basis of depression: learning from experimental models
Afridi, R., & Suk, K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.691067 · Cited by 82 · see citing works
The Role of Anxious Distress in Immune Dysregulation in Patients with Major Depressive Disorder
Gaspersz, R., Lamers, F., Wittenberg, G., Beekman, A. T. F., van Hemert, A. M., Schoevers, R. A., & Penninx, B. W. J. H. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0016-3 · Cited by 71 · see citing works
Linking atypical depression and insulin resistance-related disorders via low-grade chronic inflammation: Integrating the phenotypic, molecular and neuroanatomical dimensions
Sen, Z. D., Danyeli, L. V., Woelfer, M., Lamers, F., Wagner, G., Sobanski, T., & Walter, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.020 · Cited by 65 · see citing works
Kynurenine metabolism and inflammation-induced depressed mood: a human experimental study
Kruse, J. L., Cho, J. H.-J., Olmstead, R., Hwang, L., Faull, K., Eisenberger, N. I., & Irwin, M. R. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104371 · Cited by 59 · see citing works
Transcriptomic predictors of inflammation-induced depressed mood
Cho, J. H.-J., Irwin, M. R., Eisenberger, N. I., Lamkin, D. M., & Cole, S. W. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0316-9 · Cited by 54 · see citing works
Anti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53 · see citing works
Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials
Arnone, D., Omar, O., Arora, T., Östlundh, L., Ramaraj, R., Javaid, S., Govender, R. D., Ali, B. R., Patrinos, G. P., Young, A. H., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104965 · Cited by 53 · see citing works
Self-citation
Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder
Han, K.-M., Tae, W.-S., Kim, A., Kang, Y., Kang, W., Kang, J., Kim, Y.-K., Kim, B., Seong, J. Y., & Ham, B.-J. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.03.021 · Cited by 50 · see citing works
The Cytokine IL-17A as a Marker of Treatment Resistance in Major Depressive Disorder?
Nothdurfter, C., Milenkovic, V. M., Sarubin, N., Hilbert, S., Manook, A., Weigl, J., Almeqbaali, K., Wetzel, C. H., Rupprecht, R., & Baghai, T. C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14636 · Cited by 38 · see citing works
Identification of IL6 as a susceptibility gene for major depressive disorder
Zhang, C., Wu, Z., Zhao, G., Wang, F., & Fang, Y. (2016) · Scientific Reports · doi:10.1038/srep31264 · Cited by 46 · see citing works
Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder
Xu, Y., Liang, J., Sun, Y., Zhang, Y., Shan, F., Ge, J., & Xia, Q. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110108 · Cited by 41 · see citing works
Biological Profiling of Prospective Antidepressant Response in Major Depressive Disorder: Associations with (Neuro)Inflammation, Fatty Acid Metabolism, and Amygdala-Reactivity
Mocking, R. J. T., Nap, T. S., Westerink, A. M., Assies, J., Vaz, F. M., Koeter, M. W. J., Ruhé, H. G., & Schene, A. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.02.019 · Cited by 34 · see citing works
Exploration of 27 plasma immune markers: a cross-sectional comparison of 64 old psychiatric inpatients having unipolar major depression and 18 non-depressed old persons
Gaarden, T. L., Engedal, K., Benth, J. Š., Larsen, M., Lorentzen, B., Mollnes, T. E., Bjølseth, T. M., & Castellheim, A. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0836-x · Cited by 32 · see citing works
Genetic disposition to inflammation and response to antidepressants in major depressive disorder
Zwicker, A., Fabbri, C., Rietschel, M., Hauser, J., Mors, O., Maier, W., Zobel, A., Farmer, A., Aitchison, K. J., McGuffin, P., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.011 · Cited by 28 · see citing works
Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorder
Rashidian, H., Subramaniapillai, M., Park, C., Lipsitz, O., Zuckerman, H., Cao, B., Lee, Y., Gill, H., Rodrigues, R. N., Di Vincenzo, J. D., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221132473 · Cited by 23 · see citing works
Serum NOX1 and Raftlin as new potential biomarkers of Major Depressive Disorder: A study in treatment-naive first episode patients
Hursitoglu, O., Kurutas, E. B., Strawbridge, R., Oner, E., Gungor, M., Tuman, T. C., & Uygur, O. F. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110670 · Cited by 18 · see citing works
Self-citation
Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles
Kalkman, H. O. (2023) · Biomedicines · doi:10.3390/biomedicines11030806 · Cited by 18 · see citing works
Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway
Mandal, G., Kirkpatrick, M., Alboni, S., Mariani, N., Pariante, C. M., & Borsini, A. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae041 · Cited by 15 · see citing works
Interleukin-1 Beta in peripheral blood mononuclear cell lysates as a longitudinal biomarker of response to antidepressants: a pilot study
Ferentinos, P., Maratou, E., Antoniou, A., Serretti, A., Smyrnis, N., & Moutsatsou, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.801738 · Cited by 7 · see citing works
The Sickness Behavior Inventory-Revised: Sickness behavior and its associations with depression and inflammation in patients with metastatic lung cancer
McFarland, D. C., Walsh, L. E., Saracino, R., Nelson, C. J., Breitbart, W., & Rosenfeld, B. (2021) · Palliative and Supportive Care · doi:10.1017/s1478951520001169 · Cited by 5 · see citing works

Review for "The effect of vitamin D supplementation on mortality and Intensive Care Unit admission of COVID‐19 patients. A systematic review, meta‐analysis and meta‐regression"
(2021) · doi:10.1002/dmrr.3517/v1/review1
Review for "In search of a dose‐response relationship in SSRIs – a systematic review, meta‐analysis and network meta‐analysis"
(2020) · doi:10.1111/acps.13235/v1/review2
Review for "Dropout and adherence of obstructive sleep apnea patients to mandibular advancement device therapy: a systematic review of randomized controlled trials with meta‐analysis and meta‐regression"
(2021) · doi:10.1111/joor.13290/v1/review2
Interventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis
Türk, S., Korfmacher, A.-K., Gerger, H., der Oord, S. V., & Christiansen, H. (2023) · Clinical Psychology Review · doi:10.1016/j.cpr.2023.102271 · Cited by 29 · see citing works
Peer Review #2 of "The effectiveness of the Peyton’s 4-step teaching approach on skill acquisition of procedures in health professions education: A systematic review and meta-analysis with integrated meta-regression (v0.1)"
(2020) · PeerJ · doi:10.7287/peerj.10129v0.1/reviews/2 · Cited by 1 · see citing works

Authors: Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J.
Affiliations: King's College London (GB)
Corresponding author: Strawbridge, R.
ORCID: Strawbridge, R.
Arnone, D.
Danese, A.
Cleare, A.J.
Venue: European Neuropsychopharmacology
Publisher: Elsevier BV
Published: 2015-10
Volume: 25
Issue: 10
Pages: 1532-1543
ISSN: 0924-977X (ISSN-L)
DOI: 10.1016/j.euroneuro.2015.06.007
OpenAlex: W1922605075
Cited by: 666
References: 71
Citations by year: 2026: 38 · 2025: 68 · 2024: 54 · 2023: 55 · 2022: 69 · 2021: 91 · 2020: 78 · 2019: 62 · 2018: 55 · 2017: 46 · 2016: 40 · 2015: 7 · 2012: 1
FWCI: 2.77
Type: journal article
Language: en
Open access: green
repositorio.uchile.cl
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
Universidad de Chile (submittedVersion, cc-by-nc-nd)
Topics: Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords: depression, inflammation, treatment-resistant depression, antidepressant response, inflammatory markers, interleukin-6, TNF-α, C-reactive protein
MeSH terms: Depressive Disorder, Humans, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inflammation and clinical response to treatment in depression: A meta-analysis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks